Daiichi Sankyo Company, Limited -- Moody's affirms Daiichi Sankyo's A2 ratings; maintains stable outlook

In This Article:

Rating Action: Moody's affirms Daiichi Sankyo's A2 ratings; maintains stable outlook

Global Credit Research - 03 Aug 2020

Tokyo, August 03, 2020 -- Moody's Japan K.K. has affirmed Daiichi Sankyo Company, Limited's A2 issuer and senior unsecured ratings. The rating outlook remains stable.

The rating affirmation reflects (1) the strong progress Daiichi Sankyo has made in its antibody conjugate (ADC) projects for cancer treatments, (2) the likely revenue expansion over the next two to three years following the launch of its first ADC drug, Enhertu, and (3) the medium to long-term growth potential stemming from its promising product pipeline.

RATINGS RATIONALE

Daiichi Sankyo's A2 rating reflects its strong market position in Japan's (A1 stable) pharmaceutical industry. While its current revenue is concentrated in Japan, favorable progress in its oncology pipeline development, particularly in its ADC project, will enhance its business portfolio.

With the successful launch of the breast cancer drug Enhertu, Daiichi Sankyo has taken important steps in establishing its oncology franchise, while also improving its geographic diversification with its expansion in the US. Further, Daiichi Sankyo's collaboration with AstraZeneca PLC (A3 stable) in the development and commercialization of Enhertu and DS-1062 will accelerate its sales globally and provide funds for R&D. Successful launches of these drugs will make its product portfolio more innovative than its previous focus on cardiovascular and metabolism treatments.

Profit sharing on these ADC drugs with AstraZeneca will moderate the future upside in profit. Nevertheless, favorable test results to-date indicate Enhertu could drive revenue growth of as much as 10% annually in two to three years. In addition to breast cancer, Enhertu is undergoing clinical studies globally for applications also for lung, gastric and colorectal cancer. Further, other ADC projects in its early-stage pipeline could provide organic growth in the latter half of this decade and temper its need to make acquisitions. The company's balance sheet is very strong, with cash exceeding its debt. Moody's expects that positive free cash flow and cash will enable the company to reduce debt and further improve its already low leverage.

FACTORS THAT COULD LEAD TO AN UPGRADE OR DOWNGRADE OF THE RATINGS

The stable outlook reflects Moody's expectation that Daiichi Sankyo's revenue will grow from ADC drugs and that debt will be retired as they mature. Moody's also expects collaboration with AstraZeneca will provide earnings growth for Daiichi Sankyo, although their profit sharing arrangement will cause profit growth to lag revenue growth.